WO2011003623A3 - Procédé et marqueurs pour le pronostic individuel et/ou la détection individuelle d'une neuropathie - Google Patents

Procédé et marqueurs pour le pronostic individuel et/ou la détection individuelle d'une neuropathie Download PDF

Info

Publication number
WO2011003623A3
WO2011003623A3 PCT/EP2010/004197 EP2010004197W WO2011003623A3 WO 2011003623 A3 WO2011003623 A3 WO 2011003623A3 EP 2010004197 W EP2010004197 W EP 2010004197W WO 2011003623 A3 WO2011003623 A3 WO 2011003623A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
neuropathy
marker
prognosis
detection
Prior art date
Application number
PCT/EP2010/004197
Other languages
German (de)
English (en)
Other versions
WO2011003623A2 (fr
Inventor
Michael Sereda
Robert Fledrich
Moritz Rossner
Sven Wichert
Klaus Armin Nave
Original Assignee
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200910032418 external-priority patent/DE102009032418A1/de
Priority claimed from DE200910042090 external-priority patent/DE102009042090A1/de
Application filed by MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. filed Critical MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.
Publication of WO2011003623A2 publication Critical patent/WO2011003623A2/fr
Publication of WO2011003623A3 publication Critical patent/WO2011003623A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé de pronostic individuel de l'apparition et/ou du déroulement d'une neuropathie et/ou de diagnostic individuel d'une neuropathie chez un mammifère, notamment chez l'homme. L'invention porte également sur des marqueurs appropriés et sur des utilisations de ces marqueurs.
PCT/EP2010/004197 2009-07-09 2010-07-09 Procédé et marqueurs pour le pronostic individuel et/ou la détection individuelle d'une neuropathie WO2011003623A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102009032418.6 2009-07-09
DE200910032418 DE102009032418A1 (de) 2009-07-09 2009-07-09 Verfahren und Marker zur individuellen Prognose und/oder zur individuellenErfassung einer Neuropathie
DE102009042090.8 2009-09-18
DE200910042090 DE102009042090A1 (de) 2009-09-18 2009-09-18 Verfahren und Marker zur individuellen Prognose und/oder zur individuellen Erfassung einer Neuropathie

Publications (2)

Publication Number Publication Date
WO2011003623A2 WO2011003623A2 (fr) 2011-01-13
WO2011003623A3 true WO2011003623A3 (fr) 2011-05-05

Family

ID=42752928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/004197 WO2011003623A2 (fr) 2009-07-09 2010-07-09 Procédé et marqueurs pour le pronostic individuel et/ou la détection individuelle d'une neuropathie

Country Status (1)

Country Link
WO (1) WO2011003623A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2540824A1 (fr) 2011-06-30 2013-01-02 The Procter & Gamble Company Compositions de nettoyage comprenant une référence de variantes dýamylase à une liste de séquences
EP2551335A1 (fr) 2011-07-25 2013-01-30 The Procter & Gamble Company Composition détergente liquide enzymatique stabilisee
CN105886628B (zh) * 2016-04-29 2019-03-26 肖刻 Sprr1a基因在制备骨关节炎诊断产品中的应用
RU2019123965A (ru) 2017-02-01 2021-02-01 Дзе Проктер Энд Гэмбл Компани Очищающие композиции, содержащие варианты амилазы
CN110261619B (zh) * 2019-06-14 2021-06-25 上海四核生物科技有限公司 Prkar2b蛋白作为胃癌血清生物标志物的应用及其试剂盒
CN114040972A (zh) 2019-06-24 2022-02-11 宝洁公司 包含淀粉酶变体的清洁组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049866A2 (fr) * 2003-11-14 2005-06-02 Duke University Procede de detection de la maladie de charcot-marie de type 2a
US20050208544A1 (en) * 2002-07-09 2005-09-22 Broeckhoven Christine V Diagnostic tests for the detection of peripheral neuropathy
US20070059357A1 (en) * 2003-04-28 2007-03-15 Sankyo Company, Limited Adiponectin production enhancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208544A1 (en) * 2002-07-09 2005-09-22 Broeckhoven Christine V Diagnostic tests for the detection of peripheral neuropathy
US20070059357A1 (en) * 2003-04-28 2007-03-15 Sankyo Company, Limited Adiponectin production enhancer
WO2005049866A2 (fr) * 2003-11-14 2005-06-02 Duke University Procede de detection de la maladie de charcot-marie de type 2a

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE ncbi [online] 28 June 2009 (2009-06-28), "Homo sapiens adiponectin and collagen domain containing (ADIPOQ), mRNA", XP002610836, retrieved from ncbi accession no. NCBI:NM_004797.2 Database accession no. NM_004797.2 *
KATO KENICHI ET AL: "Serum total and high molecular weight adiponectin levels are correlated with the severity of diabetic retinopathy and nephropathy.", CLINICAL ENDOCRINOLOGY MAR 2008 LNKD- PUBMED:17970779, vol. 68, no. 3, March 2008 (2008-03-01), pages 442 - 449, XP002610837, ISSN: 1365-2265 *
SANDHU H S ET AL: "Measurement of circulating neuron-specific enolase mRNA in diabetes mellitus.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES AUG 2008 LNKD- PUBMED:18837957, vol. 1137, August 2008 (2008-08-01), pages 258 - 263, XP002610835, ISSN: 1749-6632 *

Also Published As

Publication number Publication date
WO2011003623A2 (fr) 2011-01-13

Similar Documents

Publication Publication Date Title
MX2013000917A (es) Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EP2424427A4 (fr) Marqueurs d'évènement comestibles à haute fiabilité et leurs procédés d'utilisation
IL220619A (en) Pancreatic cancer markers, detection methods, kits and their biological chips
GB2481950B (en) Surface microstructure measurement method, surface microstructure measurement data analysis method and surface microstructure measurement system.
WO2011070554A3 (fr) Dispositifs d'entrée portés aux doigts et procédés d'utilisation
PL2512226T3 (pl) Modyfikacja DP-004114-3 kukurydzy i sposoby jej wykrywania
BRPI1011201A2 (pt) métodos e sistemas de cartão de cupom.
PL2359348T3 (pl) Dokument wartościowy, sposób jego wytwarzania i sposób wykrywania zabrudzenia lub zużycia
WO2010075360A3 (fr) Procédé de détection de sepsie
EP2281903A4 (fr) Marqueur de cancer, procédé d évaluation du cancer utilisant le marqueur de cancer et réactif d évaluation
WO2011003623A3 (fr) Procédé et marqueurs pour le pronostic individuel et/ou la détection individuelle d'une neuropathie
GB2487701B (en) Cost evaluation system, method and program
HUE043280T2 (hu) Káposztafélék DP-073496-4 GAT eseménye, továbbá készítmények és módszerek annak azonosítására és/vagy detektálására
HK1184199A1 (en) Biosensor test member and method for making the same
WO2011019426A3 (fr) Systèmes de détection des alentours et procédés correspondants
WO2012012709A3 (fr) Méthodes de détection de maladies ou de pathologies cardiovasculaires
WO2011143574A3 (fr) Marqueurs biologiques plasmatiques pour le diagnostic de la maladie d'alzheimer
WO2011022099A3 (fr) Systèmes d'identification flexibles et procédés associés
EP2433115A4 (fr) Système et procédé de détection
WO2012075069A3 (fr) Signatures et déterminants associés au cancer et leurs méthodes d'utilisation
WO2013124738A3 (fr) Méthodes et biomarqueurs permettant de dépister et de pronostiquer le cancer du col utérin
WO2012036329A1 (fr) Composition ou trousse pour faire un pronostic de cancer du foie, et procédé pour faire un pronostic de cancer du foie
ZA200901955B (en) Maize event DP-098140-6 and compositions and methods for the identification and/or detection thereof
EP2638178A4 (fr) Compositions, procédés et kits pour détecter et identifier des mycobactéries
BR112012004367A2 (pt) método de detecção de adulteração.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10732870

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10732870

Country of ref document: EP

Kind code of ref document: A2